01—Abstract
Summary
Summary of the 10-K filed February 11, 2021. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 2020 10-K filing reveals a company navigating the complexities of the COVID-19 pandemic, which led to a 3.6%a decline in net sales compared to 2019.
Despite this, Stryker demonstrated resilience through strategic acquisitions, notably the significant purchase of Wright Medical Group N.V., which expanded its portfolio in trauma and extremities. The company maintained a strong focus on its core segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with MedSurg representing the largest segment by sales in 2020. Financially, Stryker reported net earnings of $1.6 billionb, a decrease from the previous year, impacted by pandemic-related disruptions and increased interest expenses due to debt financing for acquisitions.
However, operating cash flow remained robust, and the company prioritized its capital allocation strategy by investing heavily in acquisitions and continuing dividend payments, while suspending share repurchases for 2020 and 2021. Management highlighted the successful integration of acquisitions and ongoing efforts to drive innovation and operational efficiency amidst evolving market conditions and regulatory landscapes.
02—Key points
Key Highlights
- Net sales decreased by 3.6% to $14.35 billion in 2020, primarily due to the impact of the COVID-19 pandemic on elective medical procedures.
- The company completed a significant acquisition of Wright Medical Group N.V. for $4.1 billion, strengthening its position in trauma and extremities.
- MedSurg remained the largest segment by net sales ($6.4 billion), followed by Orthopaedics ($4.96 billion) and Neurotechnology and Spine ($2.99 billion).
- Net earnings declined to $1.6 billion ($4.20 per diluted share) from $2.1 billion ($5.48 per diluted share) in 2019, impacted by pandemic-related challenges and acquisition financing.
- Stryker invested $4.2 billion in acquisitions in 2020, demonstrating a commitment to growth through strategic M&A.
- Operating cash flow was strong at $3.3 billion, supporting the company's liquidity and investment strategies.
- The company suspended its share repurchase program through 2021, prioritizing other capital allocation strategies like acquisitions and dividends.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2020, Stryker Corp kept $0.11.
- Revenue$14.35B100.0%
- Cost of revenue−$5.29B36.9%
- Gross profit$9.06B63.1%
- Operating costs−$6.83B47.6%
- Operating income$2.22B15.5%
- Interest, other & tax−$624.0M4.3%
- Net income$1.60B11.1%
Where FY2020 revenue went
$14.35B- SG&A: $5.36B, 37% of revenue
- Cost of revenue: $5.29B, 37% of revenue
- Net income: $1.60B, 11% of revenue
- R&D: $984.0M, 6.9% of revenue
- Other operating costs: $489.0M, 3.4% of revenue
- Interest, other & tax: $624.0M, 4.3% of revenue
Kept 11% as net incomeNet income $1.60B · 11%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 11, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $14.35B$14.88B | −3.6% |
| Cost of Revenue | $5.29B$5.19B | +2.0% |
| Gross Profit | $9.06B$9.70B | −6.6% |
| R&D Expenses | $984.00M$971.00M | +1.3% |
| SG&A Expenses | $5.36B$5.36B | +0.1% |
| Operating Expenses | $6.83B$6.98B | −2.1% |
| Operating Income | $2.22B$2.71B | −18.1% |
| Interest Expense | $315.00M$287.00M | +9.8% |
| Net Income | $1.60B$2.08B | −23.2% |
| EPS (Basic) | $4.26$5.57 | −23.5% |
| EPS (Diluted) | $4.20$5.48 | −23.4% |
| Shares Outstanding (Basic) | 375.50M374.00M | +0.4% |
| Shares Outstanding (Diluted) | 380.30M379.90M | +0.1% |
05—Questions
Frequently Asked Questions
How did the COVID-19 pandemic impact Stryker's financial performance in 2020?
The COVID-19 pandemic significantly impacted Stryker's 2020 financial performance, leading to a 3.6% decrease in net sales. This was primarily due to the suspension of elective medical procedures, which are crucial for many of Stryker's products, particularly in the Orthopaedics segment. The pandemic also caused disruptions in supply chains and manufacturing operations.
What were the key strategic moves made by Stryker in 2020, particularly regarding acquisitions?
Stryker made a significant strategic move by acquiring Wright Medical Group N.V. for $4.1 billion. This acquisition was a key focus, strengthening Stryker's global market position, especially in trauma and extremities within the Orthopaedics segment. Another acquisition in 2020 was OrthoSensor, Inc., which focuses on digital musculoskeletal care and sensor technology for joint replacements.
How did Stryker's different business segments perform in 2020?
In 2020, the MedSurg segment generated the highest net sales at $6.4 billion, making it the largest segment. The Orthopaedics segment reported $4.96 billion in net sales, while the Neurotechnology and Spine segment had $2.99 billion. All segments experienced declines in net sales due to the pandemic's impact on elective procedures and market demand, with Orthopaedics seeing a notable decrease of 5.6%.
What is Stryker's financial health and liquidity situation based on this filing?
Stryker maintained a strong financial position with $3.02 billion in cash, cash equivalents, and marketable securities as of December 31, 2020. Operating cash flow was robust at $3.28 billion, indicating a healthy ability to generate cash from its core operations. The company had access to significant credit facilities and maintained investment-grade debt ratings, suggesting good liquidity and financial flexibility to navigate market challenges and fund future growth.
06—Continue